<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5019">
  <stage>Registered</stage>
  <submitdate>4/11/2014</submitdate>
  <approvaldate>4/11/2014</approvaldate>
  <nctid>NCT02358356</nctid>
  <trial_identification>
    <studytitle>Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study</studytitle>
    <scientifictitle>Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study</scientifictitle>
    <utrn />
    <trialacronym>CONTROL NETS</trialacronym>
    <secondaryid>CTC0120 / AG0114NET</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Midgut Neuroendocrine Tumours</healthcondition>
    <healthcondition>Pancreatic Neuroendocrine Tumours</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Neuroendocrine tumour (NET)</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Pancreatic</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other endocrine disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - octreotate
Treatment: drugs - Capecitabine
Treatment: drugs - Temozolomide

Active Comparator: PRRT - 7.8GBq 177Lu Octreotate (Lutate) given intravenously (IV) on day 1 every 8 weeks for 4 cycles.

Active Comparator: CAPTEM - Oral capecitabine 750mg/m2 b.i.d. days 1-14 and temozolomide 75mg/m2 b.i.d. days 10-14 every 28 day cycle, up to 8 cycles.

Experimental: PRRT/CAPTEM - 7.8GBq 177Lu Octreotate (Lutate) given intravenously (IV) on day 10 every 8 weeks for 4 cycles, with concurrent oral capecitabine 750mg/m2 b.i.d. days 1-14 and temozolomide 75mg/m2 b.i.d. days 10-14 up to 4 cycles.


Treatment: drugs: octreotate
7.8GBq 177Lu Octreotate (Lutate) given intravenously (IV)

Treatment: drugs: Capecitabine
oral capecitabine 750mg/m2 b.i.d.

Treatment: drugs: Temozolomide
temozolomide 75mg/m2 b.i.d.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Progression Free Survival - To determine the rate of progression free survival (PFS) at 12 months in pNETs (Group A), and at 24 months in mNETs (Group B). (PFS defined from time of randomisation to disease progression as defined by RECIST criteria version 1.1).</outcome>
      <timepoint>12 months for pNETs and 24 months for mNets</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Objective tumour response rate (partial or complete response) as per RECIST v1.1 criteria - To determine objective tumour response rate (OTRR) (partial or complete response (PR/CR)).</outcome>
      <timepoint>12 months or 24 months as appropriate</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival (death from any cause) - To determine overall survival (OS) (death from any cause).</outcome>
      <timepoint>12 months or 24 months as appropriate</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety (rates of adverse events worst grade according to NCI CTCAE v4.0) - To determine safety (rates of adverse events).</outcome>
      <timepoint>12 months or 24 months as appropriate</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life (QOL scores determined at beginning, during treatment and until disease progression) - To determine Quality of Life (QoL) (QoL scores from EORTC QLQ C30 and QLQ-GINET21 questionnaires)</outcome>
      <timepoint>12 months or 24 months as appropriate</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Resource utilisation (use of healthcare resources) and cost-effectiveness (Health utility score determined at beginning, during treatment and until end of follow up, correlated with MBS &amp; PBS data) - To determine resource utilization (costs associated with treatment regimen, MBS and PBS data, and health utilities scores from EQ-5D-5L).</outcome>
      <timepoint>12 months or 24 months as appropriate</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical Benefit - To evaluate the proportion of patients who have experienced a clinical benefit of the regimen(s). (Clinical Benefit is defined as the proportion of patients who experience complete or partial response (using RECIST v1.1) or stable disease at 12 months or 24 months as appropriate).</outcome>
      <timepoint>12 months or 24 months as appropriate</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Adults =18 years old with histologically proven, moderate to well-differentiated G1/2
             pancreatic or midgut NETs with Ki-67 &lt; 20%;

          -  The presence of somatostatin receptor avidity suitable for PRRT demonstrated on
             68Ga-octreotate PET scan;

          -  Progressive advanced/metastatic disease that has progressed during or after = 2 prior
             systemic therapies;

          -  Unresectable disease, determined by an appropriately specialized surgeon or deemed not
             suitable for liver directed therapies where liver is the only site of disease;

          -  ECOG performance status 0-2;

          -  Ability to swallow oral medication;

          -  Adequate renal function (measured creatinine clearance &gt; 50 ml/min by DTPA or
             51CR-EDTA), bone marrow function (Hb &gt; 9 g/d/L, ANC &gt; 1.5 x109L, and platelets &gt; 100 x
             10/L);

          -  Adequate liver function (serum total bilirubin = 1.5 x ULN, and Alanine
             aminotransferase (ALT), Aspartate aminotransferase (AST), Alkaline phosphatase (ALP) =
             2.5 x ULN (= 5 x ULN for patients with liver metastases)). INR = 1.5 (or on a stable
             dose of LMW heparin for &gt;2 weeks at time of enrolment .);

          -  Life expectancy of at least 9 months;

          -  Study treatment both planned and able to start within 28 days of randomisation; )

          -  Willing and able to comply with all study requirements, including treatment, timing
             and/or nature of required assessments;

          -  Signed, written informed consent.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Primary NETs other than small bowel (midgut) or pancreatic NETs;

          -  Cytotoxic chemotherapy, targeted therapy, or biotherapy within the last four weeks;

          -  Prior intrahepatic 90Y microspheres, such as SIR-Spheres in the past six months;

          -  Prior Peptide Receptor Radionuclide Therapy;

          -  Major surgery/surgical therapy for any cause within one month;

          -  Surgical therapy of loco-regional metastases within the last three months prior to
             randomisation;

          -  Uncontrolled metastatic disease to the central nervous system. To be eligible, CNS
             metastases should have been treated with surgery and/or radiotherapy and the patient
             should have been receiving a stable dose of steroids for at least 2 weeks prior to
             randomisation, with no deterioration in neurological symptoms during this time;

          -  Poorly controlled concurrent medical illness. E.g. unstable diabetes (Note: optimal
             glycaemic control should be achieved before starting trial therapy); Symptomatic NYHA
             class III or IV congestive cardiac failure, myocardial infarction within 6 months of
             start of the study, serious uncontrolled cardiac arrhythmia, unstable angina, or any
             other clinically significant cardiac disease;

          -  History of other malignancies within 5 years except where treated with curative intent
             AND with no current evidence of disease AND considered not to be at risk of future
             recurrence Patients with a past history of adequately treated carcinoma-in-situ, basal
             cell carcinoma of the skin, squamous cell carcinoma of the skin, or superficial
             transitional cell carcinoma of the bladder are eligible;

          -  Any uncontrolled known active infection, including chronic active hepatitis B,
             hepatitis C, or HIV. Testing for these is not mandatory unless clinically indicated.
             Participants with known Hepatitis B/C infection will be allowed to participate
             providing evidence of viral suppression has been documented and the patient remains on
             appropriate anti-viral therapy;

          -  Impairment of gastrointestinal function or gastrointestinal disease that may
             significantly alter the absorption of capecitabine/temozolomide (e.g., ulcerative
             disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or
             substantial small bowel resection);

          -  Presence of any psychological, familial, sociological or geographical condition
             potentially hampering compliance with the study protocol and follow-up schedule,
             including alcohol dependence or drug abuse;

          -  Pregnancy, lactation, or inadequate contraception. Women must be post-menopausal,
             infertile, or use a reliable means of contraception. Women of childbearing potential
             must have a negative pregnancy test done within 7 days prior to registration. Men must
             have been surgically sterilised or use a (double if required) barrier method of
             contraception .</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>165</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2020</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC,WA</recruitmentstate>
    <hospital>Royal North Shore Hospital - St Leonards</hospital>
    <hospital>Royal Brisbane and Women's Hospital - Herston</hospital>
    <hospital>Peter MacCallum Cancer Centre - East Melbourne</hospital>
    <hospital>Fiona Stanley Hospital - Murdoch</hospital>
    <postcode>2065 - St Leonards</postcode>
    <postcode>4029 - Herston</postcode>
    <postcode>8006 - East Melbourne</postcode>
    <postcode>6150 - Murdoch</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Australasian Gastro-Intestinal Trials Group</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Two parallel phase II randomized open label trials of Lutetium-177 Octreotate
      (177Lu-Octreotate) peptide receptor radionuclide therapy (PRRT) and capecitabine
      (CAP)/temozolomide (TEM) chemotherapy (chemo): (i) versus CAPTEM alone in the treatment of
      low to intermediate grade pancreatic neuroendocrine tumours (pNETs); (ii) versus PRRT alone
      in the treatment of low to intermediate grade mid gut neuroendocrine tumours (mNETs).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02358356</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Nick Pavlakis, Associate Professor</name>
      <address>Royal North Shore Hospital</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>NHMRC CTC</name>
      <address />
      <phone>+61 (0) 2 9562 5000</phone>
      <fax />
      <email>controlnets@ctc.usyd.edu.au</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>